PROLONG-ANG3A
Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults with Mixed Dyslipidemia
26.07.2022 – İSMAİL TÜRKAY ÖZCAN
J3F-MC-EZCV
Faz 2,randomize,çift kör,plasebo kontrollü,LY3561774 molekülünün dislipidemideki etkisi
26.07.2022 – İSMAİL TÜRKAY ÖZCAN
TQJ230(Pelacarsen)
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on cardiovascular events in patients with establishedcardiovascular disease
01.06.2021 – İSMAİL TÜRKAY ÖZCAN
SURPASS-CVOT
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
01.04.2020 – İSMAİL TÜRKAY ÖZCAN
CSL112(apolipoprotein A-I human)
A phase 3, multicenter, Double-Blind, Randomized, Placebo-Controlled, paralel- group study to investigate the efficacy and safety of CSL112 in subjects with acute coronary syndrome
15.09.2019 – İSMAİL TÜRKAY ÖZCAN
esperion
evaluation of major cardiovascular events inpatients with,or at high risc for,cardiovascular disease Who are statin intolerant traeted with bempedoic aci
22.12.2016 – 07.11.2022 İSMAİL TÜRKAY ÖZCAN
dal-GenE
HDL kolesterol
01.04.2016 – 30.10.2022 İSMAİL TÜRKAY ÖZCAN
A Randomized, Double-blind Controlled Study Comparing LCZ696 to MedicalTherapy for Comorbidities in HFpEF Patients (PARALLAX)
08.01.2018 – 10.11.2021 İSMAİL TÜRKAY ÖZCAN
Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are StatinIntolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)
Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are StatinIntolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)
15.12.2016 – 15.09.2021 İSMAİL TÜRKAY ÖZCAN
EURObservational Research Program
Atrial fibrilasyon
MERSİN ÜNİVERSİTESİ 16.09.2014 – 01.12.2020 İSMAİL TÜRKAY ÖZCAN
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 DiabetesPost Worsening Heart Failure (SOLOIST-WHF Trial)
MERSİN ÜNİVERSİTESİ 11.06.2018 – 16.11.2020 İSMAİL TÜRKAY ÖZCAN
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk(SCORED)
MERSİN ÜNİVERSİTESİ 28.11.2017 – 16.11.2020 İSMAİL TÜRKAY ÖZCAN
transition
Kalp yetm de ARNİ etkinliği
01.03.2017 – 27.06.2020 İSMAİL TÜRKAY ÖZCAN
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS)
Brief Summary:The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.Detailed Description:A multinational, randomised, double-blind, placebo-controlled phase IIIb trial to evaluate the effect of ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes mellitus
MERSİN ÜNİVERSİTESİ 01.11.2015 – 28.12.2019 İSMAİL TÜRKAY ÖZCAN
RELAX AHF 2
Efficacy Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
01.09.2015 – 31.10.2019 İSMAİL TÜRKAY ÖZCAN
CANTOS
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
22.11.2012 – 17.01.2019 İSMAİL TÜRKAY ÖZCAN
EXFORGE
Anjiotensin reseptör blokeri (ARB) ve Kalsiyum kanal blokeri kombinasyon tedavisinin esansiyel hipertansiyon hastaları üzerindeki etkinliği ve güvenilirliğine ilişkin gözlemsel çalışma
07.07.2014 – 07.07.2018 İSMAİL TÜRKAY ÖZCAN
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
MERSİN ÜNİVERSİTESİ 01.01.2016 – 14.02.2018 İSMAİL TÜRKAY ÖZCAN
CLCZ696B2228
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION)
01.01.2014 – 01.01.2017 İSMAİL TÜRKAY ÖZCAN
Spire 1
MERSİN ÜNİVERSİTESİ 01.11.2015 – 30.11.2016
Spire 2
MERSİN ÜNİVERSİTESİ 01.11.2015 – 30.11.2016
TIGRIS NIS CMC DUM 2013 1
MERSİN ÜNİVERSİTESİ 15.02.2014 – 15.09.2015
PEGASUS
Miyokard enfarktüsü olan hastalarda asetilsalisilik asit tedavisi zemininde plasebo ile karşılaştırmalı olarak Ticagrelor ile trombotik olayların önlenmesini değerlendiren randomize, çift kör, plasebo kontrollü,paralel gruplu, çok uluslu çalışma
01.10.2010 – 01.11.2014 İSMAİL TÜRKAY ÖZCAN
EFC6204 TAO Efficacy Of Otamixaban İn Unstable Angina/NSTEMI, Randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial Infarction scheduled to undergo an early invasive strategy
AKUT KORONER SENDROM
01.01.2010 – 30.09.2013 İSMAİL TÜRKAY ÖZCAN
EFC11319-ELIXA
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)
01.04.2012 – 31.12.2012 İSMAİL TÜRKAY ÖZCAN
EPICOR
Akut Koroner Sendromu olan hastalarda antitrombotik tedavinin uzun dönemli takibi çalışması”
01.03.2009 – 01.03.2011 İSMAİL TÜRKAY ÖZCAN
power24
MERSİN ÜNİVERSİTESİ 01.02.2015 – 15.09.2015